After starring in India’s first CAR-T treatment, the country’s Indian Institutes of Technology, or IITs, are set to expand their drug development footprint. Scrip takes a look at what the Indian equivalents of the Massachusetts Institute of Technology have going for them, including sizeable funding and alumni like Alphabet's CEO.

Korean bioventures join an inaugural matching event with Japanese pharma firms at Shonan iPark, amid rising hopes for further bilateral partnerships based on respective R&D capabilities.

The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.

Machines are now generating molecules that “no human would have imagined,” heard delegates at the BioAsia 2024 summit in Hyderabad, as big pharma and tech leaders discussed the many ways in which AI is causing fundamental shift in R&D approaches.